ACR Meeting Abstracts

ACR Meeting Abstracts

  • Home
  • Meetings Archive
    • ACR Convergence 2022
    • ACR Convergence 2021
    • ACR Convergence 2020
    • 2020 ACR/ARP PRSYM
    • 2019 ACR/ARP Annual Meeting
    • 2018 ACR/ARHP Annual Meeting
    • 2017-2009 Meetings
    • Download Abstracts
  • Keyword Index
  • Advanced Search
  • Your Favorites
    • Favorites
    • Login
    • View and print all favorites
    • Clear all your favorites
  • Meeting Resource Center

Session » Vasculitis – Non-ANCA-Associated & Related Disorders Poster II

Date: Monday, November 9, 2020

Time: 9:00AM-11:00AM

Meeting: ACR Convergence 2020

Abstract Number: 1918
Efficacy and Safety of Methotrexate in Giant Cell Arteritis: Results from a Bicentric Portuguese Cohort Study
Abstract Number: 1919
Efficacy & Safety of Tocilizumab in Giant Cell Arteritis: A Single Centre NHS Experience Using Imaging (Ultrasound and PET CT) as a Diagnostic and Monitoring Tool
Abstract Number: 1920
Efficacy and Safety of Tocilizumab in Patients with Giant Cell Arteritis and Visual Impairment
Abstract Number: 1921
Ongoing Vascular 18F-FDG Uptake Despite Clinical Remission in Patients Receiving Tocilizumab for Large Vessel Vasculitis-Giant Cell Arteritis: Single Universitary Center Experience of 30 Patients
Abstract Number: 1922
Association of Leukocyte Populations in Peripheral Blood and Arterial Wall Inflammation Assessed by FDG-PET in Takayasu’s Arteritis and Giant Cell Arteritis
Abstract Number: 1923
Angiographic Progression of Disease in Large-Vessel Vasculitis
Abstract Number: 1924
Low Immunogenicity in Patients with Giant Cell Arteritis Treated with Tocilizumab: 3-Year Results from the Randomized Controlled Portion and the Open-Label Follow-Up of a Phase 3 Trial
Abstract Number: 1925
Ultrasound Follow-up Examination of Intima-Media-Thickness of the Temporal and Axillary Artery over Six Months in Patients with Newly Diagnosed Giant Cell Arteritis
Abstract Number: 1926
Efficacy of Adjunctive Methotrexate in Patients with Giant Cell Arteritis Treated with Tocilizumab Plus Prednisone Tapering: Subanalysis of a Phase 3 Trial
Abstract Number: 1927
Ultrasonographic Halo Score as a Marker for Diagnosis and Monitoring of Disease Activity in GCA
Abstract Number: 1928
Quantitative Ultrasound of Temporal, Axillary and Subclavian Arteries to Monitor Tocilizumab Treatment in Patients with Newly Diagnosed Giant Cell Arteritis: A 24 Week Analysis
Abstract Number: 1929
Visual Ischemia During Relapse and Follow-up of Giant Cell Arteritis: A Systematic Review
Abstract Number: 1930
Thirty-Day Readmission Rate in Patients Who Were Initially Admitted for Active Giant Cell Arteritis
Abstract Number: 1931
Effect of Cumulative Glucocorticoid Dose and Inflammation on Weight Change During Treatment of Giant Cell Arteritis
Abstract Number: 1932
Giant Cell Arteritis – the Relationship Between the Extensiveness of Vasculitis and the Clinical Presentation
Abstract Number: 1933
Small Vessel Vasculitis Surrounding a Preserved Temporal Artery: Search for Tissue Biomarkers with Potential Diagnostic Value
Abstract Number: 1934
What Is the Significance of Periarterial Temporal Small Vessel Inflammation (SVI) on Temporal Artery Biopsy (TAB) in the Diagnosis of Vasculitis? A Systematic Review and Meta-analysis
Abstract Number: 1935
Predictors of Early Mortality for Giant Cell Arteritis at the Time of Diagnosis
Abstract Number: 1936
Prospective Analysis of Flow Velocity of the Central Retinal Artery in Newly Diagnosed Patients with Giant Cell Arteritis with Visual Symptoms and Controls
Abstract Number: 1937
Aortic Aneurysm in Giant Cell Arteritis: A Nationwide Analysis
Abstract Number: 1938
Risk for Vision Loss and Relapse in Patients with Giant Cell Arteritis
Abstract Number: 1939
Definitions and Reliability Assessment of Chronic Ultrasound Lesions of the Axillary Artery in Giant Cell Arteritis: A Study from the OMERACT Large Vessel Vasculitis Ultrasound Working Group
Abstract Number: 1940
In Newly Diagnosed Giant Cell Arteritis in a Real Life Setting Relapses Are Seen in More Than a Third of Patients – and Despite Faster Early Reduction High Cumulative Glucocorticoid Doses Are Reached
Abstract Number: 1941
Outcome of Giant Cell Arteritis Patients Who Were Primarily Admitted for Venous Thromboembolism Events
Abstract Number: 1942
Analysis of Vasculitis Patterns in Patients with Giant Cell Arteritis Compared to Patients with Giant Cell Arteritis and Polymyalgia Rheumatica
Abstract Number: 1943
The Prevalence of Anxiety and Depression in Patients with Giant Cell Arteritis
Abstract Number: 1944
Predictors of Visual Loss and Cerebrovascular Accidents in Giant Cell Arteritis
Abstract Number: 1945
Characterization of Visual Manifestations and Identification of Risk Factors for Permanent Vision Loss in Patients with Giant Cell Arteritis
Abstract Number: 1946
Fast-Track Giant Cell Arteritis Clinic Experience in the United States
Abstract Number: 1947
Risk Factors for Anxiety and Depression in Patients with Giant Cell Arteritis

« View all sessions from this meeting

Advanced Search

Your Favorites

You can save and print a list of your favorite abstracts during your browser session by clicking the “Favorite” button at the bottom of any abstract. View your favorites »

ACR Pediatric Rheumatology Symposium 2020

© COPYRIGHT 2023 AMERICAN COLLEGE OF RHEUMATOLOGY

Wiley

  • Home
  • Meetings Archive
  • Advanced Search
  • Meeting Resource Center
  • Online Journal
  • Privacy Policy
  • Permissions Policies
  • Cookie Preferences